title: Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality.
abstract: Repeated amphetamine administration is used to examine the responsivity of cerebral dopaminergic systems. Schizophrenia spectrum personality (SSP) provides a unique opportunity to study the pathophysiology of schizophrenia because of shared neurobiology without the confounding factors of acute psychosis and psychotropic exposure. Previously we noted that on repeated amphetamine administration, dyskinesia and SSP symptoms were less likely to worsen in SSP than in healthy volunteers. In the current study, we report the effects of repeated amphetamine on antisaccade task performance. Eleven SSP and seven healthy subjects were given placebo once and amphetamine (30 mg) twice, in randomized double-blind fashion at least 1 week apart. Antisaccade eye measurements (error rate and latency) were recorded over 30 trials in each direction. Analysis of error rate showed no significant main effects of the drug. There was a significant group by field by drug interaction effect on the antisaccade latency. The SSP group showed a significant reduction in antisaccade latency for right field targets whereas no significant effects were noted in healthy control subjects. Findings from this preliminary study suggest SSP may be more receptive to the beneficial effects of repeated amphetamine on cognition than healthy controls.
authors.affiliation: Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. iwonodi@mprc.umaryland.edu
authors.forename: Ikwunga
authors.initials: I
authors.lastname: Wonodi
authors.forename: Shawn L
authors.initials: SL
authors.lastname: Cassady
authors.forename: Helene
authors.initials: H
authors.lastname: Adami
authors.forename: Mathew
authors.initials: M
authors.lastname: Avila
authors.forename: Gunvant K
authors.initials: GK
authors.lastname: Thaker
mesh_terms: D000328:Adult; D000661:Amphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology*; D004334:Drug Administration Schedule; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D008297:Male; D010507:Periodicity; D012438:Saccades / Q000187:drug effects*; D012569:Schizotypal Personality Disorder / Q000453:epidemiology* / Q000503:physiopathology*
chemical_list: D000697:Central Nervous System Stimulants; D000661:Amphetamine